2026 Global: Apheresis Market-Competitive Review (2032) report
Description
The 2026 Global: Apheresis Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for apheresis market by geography and historical trend. The scope of the report extends to sizing of the apheresis market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The apheresis market features ten major companies driving innovation in blood separation and therapeutic applications: Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), Cerus Corporation (U.S.), B. Braun Melsungen AG (Germany), HemaCare Corporation (U.S.), Kaneka Corporation (Japan), and Nikkiso Co., Ltd. (Japan). These firms dominate through advanced centrifugation and membrane filtration technologies, supporting plasmapheresis, plateletpheresis, and treatments for neurological disorders, autoimmune conditions, and chronic kidney disease. Haemonetics leads with systems like NexSys PCS for efficient plasma collection, while Fresenius excels in dialysis-integrated apheresis via its global network of 4,000 clinics treating over 349,000 patients. Terumo BCT's Spectra Optia platform advances therapeutic apheresis and cell therapy, and Asahi Kasei focuses on bioprocess expansions in China.
Fresenius Medical Care and B. Braun Melsungen AG strengthen their positions with comprehensive healthcare portfolios, including 5,000 products from B. Braun and Fresenius's preclinical milestones in regenerative medicine. Cerus Corporation innovates pathogen reduction via the INTERCEPT Blood System, approved for cryoprecipitate in 2020, enhancing blood safety worldwide. Kawasumi Laboratories and Kaneka Corporation contribute Japanese precision engineering for disposables and filtration, while Nikkiso expands from industrial instruments into blood purification with high global market share. HemaCare, now under Charles River Laboratories, supports research in cellular therapies. Collectively, these companies fuel market growth at 7.82-9.2% CAGR, projecting from $2.07-2.68 billion in 2023-2024 to $3.50-5.91 billion by 2030-2034.
North America holds the largest share due to reimbursement policies and infrastructure, with Asia Pacific emerging fastest via rising awareness and R&D. Strategies like mergers, FDA approvals (e.g., Haemonetics' 2020 plasma tech), and regional expansions solidify dominance, amid demand for automated, safe systems in hospitals and blood centers. Terumo and Asahi Kasei lead in cellular technologies, while Baxter International and Medica SPA add competition in disposables. This ecosystem addresses rising chronic diseases, ensuring robust plasma-derived therapies and transfusion medicine advancements.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for apheresis market by geography and historical trend. The scope of the report extends to sizing of the apheresis market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The apheresis market features ten major companies driving innovation in blood separation and therapeutic applications: Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), Cerus Corporation (U.S.), B. Braun Melsungen AG (Germany), HemaCare Corporation (U.S.), Kaneka Corporation (Japan), and Nikkiso Co., Ltd. (Japan). These firms dominate through advanced centrifugation and membrane filtration technologies, supporting plasmapheresis, plateletpheresis, and treatments for neurological disorders, autoimmune conditions, and chronic kidney disease. Haemonetics leads with systems like NexSys PCS for efficient plasma collection, while Fresenius excels in dialysis-integrated apheresis via its global network of 4,000 clinics treating over 349,000 patients. Terumo BCT's Spectra Optia platform advances therapeutic apheresis and cell therapy, and Asahi Kasei focuses on bioprocess expansions in China.
Fresenius Medical Care and B. Braun Melsungen AG strengthen their positions with comprehensive healthcare portfolios, including 5,000 products from B. Braun and Fresenius's preclinical milestones in regenerative medicine. Cerus Corporation innovates pathogen reduction via the INTERCEPT Blood System, approved for cryoprecipitate in 2020, enhancing blood safety worldwide. Kawasumi Laboratories and Kaneka Corporation contribute Japanese precision engineering for disposables and filtration, while Nikkiso expands from industrial instruments into blood purification with high global market share. HemaCare, now under Charles River Laboratories, supports research in cellular therapies. Collectively, these companies fuel market growth at 7.82-9.2% CAGR, projecting from $2.07-2.68 billion in 2023-2024 to $3.50-5.91 billion by 2030-2034.
North America holds the largest share due to reimbursement policies and infrastructure, with Asia Pacific emerging fastest via rising awareness and R&D. Strategies like mergers, FDA approvals (e.g., Haemonetics' 2020 plasma tech), and regional expansions solidify dominance, amid demand for automated, safe systems in hospitals and blood centers. Terumo and Asahi Kasei lead in cellular technologies, while Baxter International and Medica SPA add competition in disposables. This ecosystem addresses rising chronic diseases, ensuring robust plasma-derived therapies and transfusion medicine advancements.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
